Opinion

Video

ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

Author(s):

Kelly E. McCann, MD, PhD,Sara A. Hurvitz, MD, FACP

A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.

Video content above is prompted by the following:

IOs, PARPi

Related Videos
5 experts are featured in this series
5 experts are featured in this series
2 expert is featured in this series.
Related Content
Breast cancer | Image Credit: ©Sebastian Kaulitzki – stock.adobe.com
January 28th 2025

Inavolisib Plus Palbociclib/Fulvestrant Shows OS Benefit in Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Breast Cancer

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

FDA
January 20th 2025

FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
January 17th 2025

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer

Erica L. Mayer, MD, MPH
January 13th 2025

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer